miR-326 is significantly increased in peripheral blood leukocytes of MS patients, and is prominently expressed by CD4+/IL17a+ T cells compared to other T cell and non-T cell populations (Du et al., 2009). This evidence concerns the gene CD4 and myeloid sarcoma.